Biocon shares jump 2% after UK approval to diabetes drug

So far in 2024, the stock has rallied over 2 percent, marginally outperforming benchmark Nifty which has tisden around 12 percent during this period.

Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *